Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy in the world ([@bib5]). Despite significant advances in treatment modalities, such as surgery and chemoradiotherapy (CRT), local and distant recurrence is encountered in ∼30% of the cases ([@bib5]). Hence, there is an imperative need to identify novel biological markers that predict patients at high risk of disease recurrence.

HNSCC has been associated with a variety of aetiological agents, such as alcohol consumption, tobacco use and human papillomavirus (HPV) infection. Approximately 20-25% of patients are HPV-positive, most prominently subtype 16 ([@bib12]). HPV-positive patients present better response to RT/CRT and are characterised by a more favourable prognosis compared with HPV-negative patients ([@bib4]). Immunohistochemical detection of the cell cycle regulatory protein p16^INK4a^ has been commonly used to validate HPV infection ([@bib29]).

Immune-regulated pathways influence several aspects of malignant development, and cancers present a highly immunosuppressive microenvironment that promotes tumour progression ([@bib9]). In that context, tumor-associated macrophages (TAMs) have been identified as key regulators of tumour immunosuppression, angiogenesis, migration, metastasis and treatment evasion ([@bib45]; [@bib16]). Macrophages can be polarised towards either M1 or M2 macrophages. M1 macrophages activate type 1 helper T cells (Th1) and foster the immune response against pathogens or malignant cells, whereas M2 macrophages lead to an anti-inflammatory response that promotes tumour cell growth and metastasis ([@bib45]; [@bib16]). In a similar fashion, myeloid-derived suppressor cells, such as CD11b+ myeloid cells, mediate tumour immunosuppression, restoration of tumour vasculature and refractoriness to RT ([@bib21]; [@bib16]).

TAMs have been associated with poor prognosis in glioma, lymphoma, melanoma, sarcomas, breast and lung cancer ([@bib31]; [@bib24]; [@bib47]; [@bib14]; [@bib38]; [@bib48]; [@bib33]; [@bib44]). CD68 has been commonly used as a macrophage marker for immunohistochemistry but is essentially a pan-macrophage marker that is unspecific to the monocyte/macrophage lineage. CD163 is a transmembrane scavenger receptor for haptoglobin--hemoglobin complexes that is predominantly regarded as a specific monocyte/macrophage marker for M2 macrophages ([@bib30]; [@bib45]; [@bib3]).

Although previous reports have examined the role of TAMs in HNSCC, the majority of the studies included patients treated with surgery ([@bib32]; [@bib36]; [@bib41]; [@bib20]), whereas the prognostic value of TAMs in patients treated with definitive CRT remains unknown. Similarly, the impact of CD11b+ myeloid cells in patients with HNSCC has not been explored. In the present study, we examined the prognostic value of CD68, CD163 and CD11b in pretherapeutic core biopsy samples from 106 patients treated homogeneously with definitive CRT. Biopsies from *n*=12 early local tumour recurrences were available, and hence we also assessed TAMs and blood vessel density in those 12 samples and compared expression with their matched primary tumours. Finally, the prognostic significance of TAMs according to the surrogate marker p16^INK4a^ (HPV16) status was investigated.

Patients and methods
====================

Patients
--------

Between 2007 and 2011, a total of 106 patients with histologically confirmed locally advanced HNSCC received definitive CRT at the Department of Radiotherapy and Oncology, University Hospital Frankfurt am Main, Germany. Tumour diagnosis and staging were based on physical examination, baseline tumour biopsy, CT/MRI of head and neck and chest/abdomen, chest X-ray and full blood count. Tumour staging was performed in accordance with the Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer. Inclusion criteria were as follows: histopathological diagnosis of HNSCC; age⩾18 years; good blood, liver and renal function; lack of metastasis and/or second cancer; curative intent. Ethical approval for the present study was obtained from the local ethics committee of Goethe University Frakfurt, Germany.

Treatment protocol and follow-up
--------------------------------

Treatment was applied using either a 3D-based RT or intensity-modulated RT and immobilisation with thermoplastic masks. CT and MRI scans were used for target volume delineation. A prophylactic feeding tube was inserted before commencing CRT. The latter was administered using ⩾6 MeV energy photon beams once daily with standard fractionation of 1.8--2 Gy to a total dose of 70--72 Gy. During the second half of the RT (following 15 fractions of 2 Gy to a dose of 30 Gy), a hyperfractionated accelerated fractionation schedule (1.4--1.5 Gy twice daily) was used as described ([@bib11]). Four patients received a different RT fractionation schedule. Chemotherapy consisted of 5-FU (600 mg m^−2^ per day) as a continuous 120-h intravenous infusion and Cisplatin (20 mg m^−2^ per day) as short intravenous infusion, both administered on days 1--5 and 29--33 of RT. Patients with poor kidney function (\<60 ml h^−1^ creatinine clearance) instead received carboplatin or mitomycin-C. A reduction in chemotherapy dose was considered in case of leukopenia (leucocyte count \<3 nl^−1^) and/or thrombocytopenia (platelet count\<100 000 nl^−1^). Definitive CRT was applied following presentation of the case to the weekly Head and Neck Cancer multidisciplinary tumour board in the following cases: (1) ⩾T3-stage; (2) patients with poor general health status who were considered inoperable; and (3) patients who have electively opted for CRT.

Follow-up was performed 6 weeks upon completion of CRT and thereafter at 3-month intervals and included clinical examination with endoscopy and CT/MRI imaging. Patients with suspicious clinical and radiologic findings received a biopsy. Patient characteristics are shown in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}.

Immunohistochemical evaluation of CD68, CD163, CD11b, p16^INK4a^ and CD31
-------------------------------------------------------------------------

Formalin-fixed, paraffin-embedded blocks from pre-treatment tumour biopsies and tumour recurrences were provided by the Institute for Pathology, University Hospital Frankfurt archives. Immunohistochemical detection of CD68, CD163 and CD11b were performed with a horseradish-peroxidase technique using a DAKO Autostainer Link 48 (DAKO, Hamburg, Germany). Antigens were retrieved following pre-treatment of microscope slides (Star Frost, Engelbrecht, Germany) with an Epitope Retrieval Solution (Trilog, Cell Marque, Rocklin, CA, USA) for 30 min. A standardised Dako EnVision FLEX Peroxidase Blocking reagent (K800, DAKO) and mouse monoclonal antibodies for CD68 (IS609, DAKO), CD163 (dilution 1 : 100, Cell Marque), and rabbit polyconal CD11b (dilution 1 : 100, Novus Biologicals, Littleton, CO, USA) were used for immunostaining following incubation for 20 min at room temperature. Visualisation was performed using a dextran polymer-conjugated horseradish-peroxidase and 3,3′-diaminobenzidine chromogen followed by counterstaining with hematoxylin solution (Gill 3, Sigma Aldrich, Munich, Germany). For each staining, negative control slides (absent primary antibody) were included as well. Immunohistochemical staining of p16^INK4a^ protein (HPV16) has been previously described ([@bib7]). CD31 immunohistochemistry was performed using a mouse anti-human CD31 antibody diluted 1 : 200 (clone JC70A Dako, Glostrup, Denmark) and the Discovery XT automated IHC system (Ventana, Tucson, Arizona) as we reported before ([@bib8]).

Immunohistochemistry scoring
----------------------------

We performed a semi-quantitative scoring of TAMs by measuring the density of CD68+, CD163+ and also of myeloid CD11b+ cells as follows:(1) no, or sporadic cells; (2) moderate numbers of cells; (3) abundant occurrence of cells; and (4) highly abundant occurrence of cells. We evaluated TAMs in three different tumour compartments: the intraepithelial compartment, the stroma, and the tumour periphery in three random fields ( × 10 magnification). Necrotic areas were excluded from the analysis. The total score of CD68, CD163 and CD11b immunostaining was calculated as the sum of the individual scores from the three tumour compartments (intraepithelial compartment, stroma and tumour periphery), respectively. The total score ranged from 3 to 12. We used the median value as a cutoff value to separate the patient cohort into two groups with either low or high CD68, CD163 and CD11b expression.

We also evaluated the prognostic significance of the TAMs score for each of the three different tumour compartments (intraepithelial compartment, stroma and tumour periphery) separately. For that purpose, we calculated the median TAMs score of each area and the cutoff point was used to separate the cohort into two groups with either low or high TAMs score. To validate the semi-quantitative scoring of TAMs expression, the number of cells was measured in three randomised × 10 magnification fields per sample. Following that, the median cell number was used as a cutoff point to separate the patient cohort into two groups with either low or high TAMs cell number.

Additionally, the prognostic value of HPV16 based on the HPV16 immunoreactivity (positive *vs* negative) was investigated. The prognostic value of TAMs was assessed separately in HPV16-positive and HPV16-negative patients.

Biopsy material of early local recurrences from the high radiation dose area was available in *n*=12 patients. Hence, we assessed TAMs expression in those 12 patients and their median cell number was compared with their matched primary tumours ( × 10 magnification field; 3--4 images per tumor). Primary tumours and matched recurrent samples were also stained with hematoxylin and eosin (H&E) as previously described ([@bib19]). CD31-based blood vessel density in the *n*=12 recurrent tumours and their matched samples was assessed as reported ([@bib8]).

To minimise interobserver variability, scoring was performed by two independent investigators (PB and EF) without knowledge of the clinicopathological data. In case of discrepancy, a consensus was drawn following re-examination of the slides at the microscope. Images were acquired using an AxioImager Z1 microscope, equipped with an Axiocam camera and Axiovision 4.6 software (Zeiss, Göttingen, Germany).

Examination of diagnostic images and RT plans in recurrent tumours
------------------------------------------------------------------

To determine the area of local recurrence, we examined the diagnostic images (CT and MRI) and initial radiotherapy plans of the 12 patients. The recurrent tumour was contoured using the Oncentra Masterplan planning software (Nucletron, Veenendaal, The Netherland) and co-registered with the initial planning computed tomography scan of the primary tumour to assess the pattern of local failure after CRT.

Statistical analysis
--------------------

The Fisher\'s exact test was used to assess the differences between categorical variables. Overall survival (OS) and time to recurrence were measured from the start of CRT diagnosis to the day of death and recurrences, respectively. Patients without tumour recurrence were censored at the last follow-up contact. Progression-free survival (PFS) was defined as the time between the beginning of CRT diagnosis and tumour relapse (locoregional recurrence and/or distant metastases) or death owing to tumor-unrelated causes. Local failure-free survival (LFFS) was calculated from the beginning of CRT to the first local tumour detection after CRT (i.e. non-complete response), local tumour recurrence after complete response or death from any cause. Distant metastases-free survival (DMFS) was assessed separately. Significance was defined as a *P*\<0.05. Survival curves were plotted by using the Kaplan--Meier method. Univariate and multivariate analysis were performed using the log-rank (Mantel--Cox) test and the Cox proportional hazard models, respectively. Statistical analyses were performed using the SPSS Version 19 statistical programme (version 15.0, IBM, Amonk, NY, USA) and the Graphpad Prism version 4.0 (GraphPad Software, La Jolla, CA, USA).

Results
=======

TAMs expression in primary tumours and correlation with clinicopathologic parameters
------------------------------------------------------------------------------------

[Table 1](#tbl1){ref-type="table"} shows the immunohistochemistry characteristics and labelling scores for CD68, CD163 and CD11b, based on the median cutoff value of immunohistochemistry score. With regard to TAMs correlation to clinicopathological parameters, ([Table 2](#tbl2){ref-type="table"}), a significantly higher incidence of N2-3 stage that is, advanced lymphadenopathy was found in patients with higher CD68 expression (97.2%) compared with patients with low CD68 expression (80%). Interestingly, the incidence of cN2c-3 stage was higher in patients with low CD68 expression, which is likely cohort related. Also, 20% of patients with low CD68 expression presented cN0-1 stage compared with only 2.8% in those with high CD68 expression, indicating a more aggressive disease phenotype (*P*=0.003). We failed to identify any other significant relationship between TAMs expression and clinicopathologic parameters ([Table 2](#tbl2){ref-type="table"}).

TAMs in primary tumours and correlation with clinical outcome
-------------------------------------------------------------

After a median follow-up of 40 months (range, 2.3--72 months), OS at 2 years was 60.5% for the entire cohort. In univariate analysis, patients with high CD68 expression had a significantly worse OS (low *vs* high CD68: mean 48.0 *vs* 31.9 months; *P*=0.017), PFS (low *vs* high CD68: mean 43.5 *vs* 27.6 months; *P*=0.010), LFFS (low *vs* high CD68: mean 44.0 *vs* 28.0 months; *P*=0.006) and DMFS (low *vs* high CD68: mean 46.6 *vs* 30.8 months; *P*=0.011) ([Figure 1A](#fig1){ref-type="fig"} and [Table 3](#tbl3){ref-type="table"}). Similarly, high CD163 expression was associated with unfavourable outcome. Indeed, patients with low CD163 expression presented a better OS (low *vs* high CD163: mean 48.7 *vs* 34.1 months; *P*=0.007), PFS (low *vs* high CD163: mean 45.3 *vs* 28.3 months; *P*=0.006), LFFS (low *vs* high CD163: mean 45.6 *vs* 29.0 months; *P*=0.007) and DMFS (low *vs* high CD163: mean 48.0 *vs* 32.1 months; *P*=0.010) ([Figure 1B](#fig1){ref-type="fig"} and [Table 3](#tbl3){ref-type="table"}). CD11b expression did not affect outcome in univariate analysis. Of note, univariate analysis failed to detect a statistical significance for the clinicopathological parameters with regard to the clinical end points ([Table 3](#tbl3){ref-type="table"}). In the Cox model (multivariate analysis), only high CD163 expression was confirmed as an independent prognostic parameter for worse OS (*P*=0.010), PFS (*P*=0.033), LFFS (*P*=0.036) and DMFS (*P*=0.038) ([Table 3](#tbl3){ref-type="table"}).

Importantly, we validated the semi-quantitative scoring of TAMs expression by measuring the median number of cells per tumour field ( × 10 magnification) and confirmed the prognostic value of CD68 and CD163 for all four clinical end points ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}; [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}).

Additionally, we examined the prognostic value of TAMs expression, based on the three different tumour compartments (intraepithelial, tumour stroma and tumour periphery; [Supplementary Table 3](#sup1){ref-type="supplementary-material"}; [Supplementary Figure 2A and B](#sup1){ref-type="supplementary-material"}). Interestingly, we observed differences in prognostic significance of TAMs that was dependent on the tumour compartment. Indeed, high expression of CD68 in tumour stroma was significantly associated with worse OS (*P*=0.010), PFS (*P*=0.009), LFFS (*P*=0.004) and DMFS (*P*=0.012), whereas differences in CD68 expression in intraepithelial compartment and periphery did not have a prognostic impact. Similarly to CD68, low CD163 expression in tumour stroma was associated with superior OS (*P*=0.006), PFS (*P*=0.001) and LFFS (*P*=0.001) and DMFS (*P*=0.003), whereas CD163 expression in tumour cell and periphery did not affect outcome. CD11b analysis in the different tumour compartments did not show significance for any of the clinical end points ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}). Representative examples of tumours with low and high stromal CD68 and CD163 expression are shown in [Figure 2](#fig2){ref-type="fig"}.

TAMs in recurrent tumours
-------------------------

Furthermore, we examined the expression of TAMs in available biopsy samples from 12 patients that developed early local recurrence and compared it with their matched primary tumour samples ([Figures 3A--C](#fig3){ref-type="fig"}). We failed to detect a significant difference in CD68+ and CD163+ cell numbers between the early recurrence and their matched primary tumour biopsy samples. In contrast, examination of the recurrence samples in 10 of the 12 patients with early recurrence demonstrated a significant increase in the number of CD11b+ cells (*P*=0.0097) compared with their matched primary samples. Recurrent tumours showed significantly lower vascular density (*P*=0.0004) compared with their matched primary samples ([Supplementary Figure 3A](#sup1){ref-type="supplementary-material"}). H&E staining of the primary tumours demonstrated increased fibrosis in recurrent tumours, which is expected owing to previous CRT ([Supplementary Figure 3B](#sup1){ref-type="supplementary-material"}).

Assessment of the diagnostic images and RT plans showed that in all 12 patients local recurrences occurred in the high radiation dose area, located within the 95% isodose of the prescribed dose of ⩾70 Gy ([Supplementary Figure 3C](#sup1){ref-type="supplementary-material"}).

TAMs in correlation with HPV16 status
-------------------------------------

Finally, we analysed the prognostic value of HPV16 alone as well as in correlation with CD163 that showed significance in multivariate analysis and CD11b ([Supplementary Tables 4 and 5](#sup1){ref-type="supplementary-material"}; [Supplementary Figure 4A and B](#sup1){ref-type="supplementary-material"}). HPV16 status in primary tumours did not predict for clinical outcome. CD163 in primary tumours presented a strong prognostic value only in HPV-negative patients (PFS: *P*=0.024; LFFS: *P*=0.028; and DMFS: *P*=0.045), except for OS (*P*=0.077). Again, CD11b did not affect any of the four clinical end points in correlation to HPV16. Images of tumours with positive and negative HPV16 expression are shown in [Supplementary Figure 4B](#sup1){ref-type="supplementary-material"}.

Discussion
==========

In the present work, patients with high expression of CD163+ TAMs in their primary tumours presented significantly worse clinical outcome compared with patients with low infiltration by TAMs. This observation was independent of clinicopathological factors with a predictive role in this disease.

In line to our findings, several studies have shown a pro-tumorigenic role for TAMs ([@bib16]) and demonstrated a significant association between high levels of TAMs and unfavourable prognosis in patients with various malignancies ([@bib31]; [@bib24]; [@bib47]; [@bib14]; [@bib38]; [@bib48]; [@bib33]; [@bib44]). However, immunohistochemical analysis in most of these studies was restricted to CD68, a pan-macrophage marker that recognises both tumoricidal (M1) and anti-inflammatory pro-tumorigenic (M2) macrophages, whereas only few have incorporated the use of an M2-specific TAMs marker, such as CD163 ([@bib30]; [@bib45]; [@bib3]). Here, we included the assessment of an antibody against CD163 to identify these TAMs.

With regard to HNSCC, only few reports on the prognostic relevance of TAMs have been published so far. The majority of these studies included patients treated with surgery that did not analyse the impact of TAMs on survival ([@bib25]). [@bib32], [@bib41] and [@bib36] showed that TAMs were associated with advanced stage and higher pathological grade in surgically treated patients with oral cancer [@bib46] failed to detect a prognostic value for CD68+ TAMs after studying immune cell infiltration patterns in 33 patients treated by surgery. In 108 patients with HNSCC who received surgical resection, CD163 was correlated with worse OS ([@bib20]), as in our work. However, even though 62 of these patients presented with advanced disease (Stage III--IV), they did not receive adjuvant treatment and the tumour resection status (R0- *vs* R1/R2-resection) was not reported that makes interpretation of these findings challenging. In contrast to the above mentioned studies, an important strength of our work relies on the fact that it includes a large cohort of patients (*n*=106) treated homogeneously with definitive CRT in a single institution.

We observed differences in the prognostic value of CD68+ and CD163+ TAMs that varied according to the tumour compartment. High CD68+ and CD163 expression in tumour stroma was associated with worse prognosis, whereas TAMs infiltration in the intraepithelial compartment or tumour periphery did not affect outcome. The tumour microenvironment is characterised by the accumulation of different host-derived stroma cells, such as TAMs. Indeed, TAMs are a major component of tumour stroma. The interaction between tumour cells and stromal TAMs aggravates the inflammatory response, leading to tumour progression ([@bib16]). Additionally, accumulating evidence suggests targeting the stromal TAMs as an effective anticancer therapy ([@bib23]; [@bib34]). These data support our findings regarding the predictive role of TAMs in the stromal compartment in our series. To the best of our knowledge, the present study is the first to examine in detail the prognostic significance of TAMs in the different tumour compartments in HNSCC. Notably, our results are in line with previous reports demonstrating a correlation between high stromal TAMs expression and worse cancer-specific and OS in patients with other tumours , such as breast and lung cancer and melanoma ([@bib24]; [@bib14]; [@bib38]).

HPV16-positivity was not associated with more favourable prognosis in our series, which is inconsistent with studies showing better survival in HPV-positive patients following CRT ([@bib29]; [@bib4]). We believe that this discrepancy is possibly due to the low number of patients with oropharyngeal cancer and the high percentage of older patients in our cohort. Interestingly, high expression of CD163+ TAMs was associated with worse clinical outcome only in HPV16-negative patients in our study. The prognostic impact of TAMs with regard to HPV status remains unclear. A recent work demonstrated CD68+ TAMs colocalisation with the programmed cell death-1 ligand in HPV-positive HNSCC that likely suppress anti-tumour T-cell functions ([@bib35]). Additional work is needed to elucidate the correlation of TAMs and HPV.

Preclinical studies have suggested recruitment of TAMs, including CD11b+ myeloid cells, a member of the integrin family, as a resistance mechanism to RT ([@bib28]; [@bib18]; [@bib37]). Indeed, several groups have shown that ionising radiation can, via vascular damage and induction of hypoxia, lead to the upregulation of hypoxia inducible factor 1, activation of cytokine signalling and recruitment of TAMs that result in restoration of vasculature, immunosuppression and tumour progression ([@bib39]; [@bib40]; [@bib6]; [@bib1]; [@bib13]; [@bib2]; [@bib26]; [@bib28]). [@bib39] showed that high TAMs expression in tumours enhanced tumour regrowth in pre-irradiated tumour beds. In a preclinical work, CD11b+ cell density after 10 daily fractions of 1.84--2 Gy correlated with the TCD50 (dose to cure 50% of the tumours ) after 30 fractions, suggesting that CD11b+ cells may affect local tumour control after fractionated irradiation ([@bib51]). In a recent study, irradiation-mediated activation of the v-abl Abelson murine leukaemia viral oncogene homologue 1 kinase upregulated the macrophage colony-stimulating factor 1 (CSF1). The latter resulted in increased recruitment of CSF1R-expressing CD11b+ myeloid cells and TAMs that promoted tumour regrowth following RT in a prostate cancer model, whereas a CSF1R inhibitor enhanced response to radiation ([@bib50]). [@bib26] observed increased intratumoral infiltration by CD11b+ cells in preclinical models and patients with glioblastoma that promoted recurrence via vasculogenesis after RT. Irradiation of mouse mammary tumours increased influx of CD11b+ cells that, via expression of matrix metalloproteinase-9, led to vascular restoration, contributing to tumour regrowth ([@bib1]; [@bib2]). In a similar fashion, Jain and colleagues have found increased CD11b+ cell counts in irradiated tumours ([@bib27]). Targeting CD11b+ cells either by a monoclonal antibody or depletion of the bone marrow compartment improved RT response and prevented recurrence, whereas infusion of CD11b+ myeloid cells enhanced tumour regrowth after local radiation ([@bib2]; [@bib26]; [@bib27]). The above data indicate that CD11b+ myeloid cells can facilitate tumour recurrence following RT.

For these reasons, we examined TAMs, including CD11b+ cells, in *n*=12 available samples of early local recurrence and their matched primary tumours. We did not find a significant difference in either CD68+ or CD163+ cell infiltration between the recurrences and their matched primary tumour samples. In contrast, examination of the recurrence samples demonstrated a significant increase in the number of CD11b+ cells that occurred in 10 out of the 12 patients compared with their matched primary samples. Vascular density of the early recurrent tumours was significantly lower compared with their matched primary samples in our series. Local recurrences in all 12 patients occurred in the high radiation dose area (⩾70 Gy), the common pattern of failure in HNSCC after RT ([@bib15]; [@bib22]).

Our data show that CD11b+ myeloid cells can be associated with tumour recurrences following CRT and raise important questions. First, in the clinical setting where daily fractionation doses of 1.4--2 Gy are used, it remains unclear whether these cells infiltrate the tumour already at an early stage during and/or following CRT, as it has been demonstrated for high single radiation doses (15--20 Gy) in preclinical studies ([@bib1]; [@bib2]; [@bib26]; [@bib27]), or whether CD11b+ cell influx increases in parallel to the growth of the recurrent tumor. Similarly to our present findings in HNSCC, Brown and colleagues also found higher levels of CD11b+ cells in recurrent glioblastomas compared with their matched baseline primary tumours ([@bib26]), but additional clinical reports are lacking. Hence, it will be interesting to compare the expression of myeloid cells between primary tumours and matched recurrences also in other tumour histologies to see whether this phenomenon occurs in the wider setting after RT/CRT. Second, although the mechanism remains under investigation, CD11b+ cells can help restore tumour vasculature after large single irradiation doses ([@bib2]; [@bib26]; [@bib27]; [@bib29]). Interestingly, in our series, vascular density was significantly lower in recurrent tumours compared with their matched primary samples. Thus, CD11b could have contributed to the growth of tumour recurrence via a mechanism other than restoration of vasculature, such as immune evasion. Third, as expected for recurrent tumours previously treated with CRT, H&E analysis of the recurrence specimens revealed increased fibrosis but whether fibrotic tissue could stimulate (or be associated with) CD11b+ cell recruitment in tumour recurrences remains largely unexplored. Preclinical studies in non-malignant fibrotic diseases, such as pulmonary and cardiac fibrosis, have reported expression of CD11b+ cells ([@bib43]; [@bib49]). Fourth, patients in our study were treated with cisplatin/5-FU-based CRT, and hence we cannot exclude that chemotherapy also fostered myeloid cell recruitment in recurrent tumours. Indeed, there is compelling evidence that chemotherapy drugs, including cisplatin and 5-FU, can result in recruitment of myeloid cells to mediate tumour resistance to treatment ([@bib17]; [@bib42]; [@bib10]; [@bib16]). Fifth, the precise origin of these cells in patients with tumour recurrences remains largely unexplored. Importantly, in the present work, the expression of CD11b+ cells in the recurrent samples differed from CD68+ and CD163+. Thus, CD11b+ cells might reflect a different population than CD68+ and CD163+ cells in patients with HNSCC recurrence. Indeed, there are several CD11b+ cell subgroups characterised by different myeloid origin according to myeloid-derived suppressor cell markers, such as CD14, CD33 and human leukocyte antigen D-related ([@bib21]), which could also explain the lack of prognostic value for CD11b+ cells in primary tumours.

Our study has limitations. First, although patients were treated and followed up prospectively, the retrospective analysis of TAMs cannot exclude potential selection bias. Second, despite the relatively long median follow-up of 40 months, a longer follow-up is needed. Third, our findings on CD11b+ cells were obtained from a small number of recurrent tumours (*n*=12) and hence need validation in larger cohort.

Taken together, high primary tumour CD163+ TAMs expression was associated with worse outcome in patients with HNSCC following definitive CRT. Early local recurrences showed increased infiltration by CD11b+ cells. These data highlight TAMs as potential biomarkers for risk stratification and hence patients may benefit from novel agents that target TAMs in combination with RT/CRT.
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![**Prognostic significance of the TAMs markers (**A**) CD68 and (**B**) CD163 with regard to overall survival (OS), progression-free survival (PFS), locoregional failure-free survival (LFFS) and distant metastases-free survival (DMFS) in patients with head and neck cancer following definitive chemoradiotherapy.**](bjc2014446f1){#fig1}

![**Examples of tumour samples with low and high stromal (**A**) CD68 and (**B**) CD163 expression.** Areas of interest are depicted as dotted lines (tumor) or arrows (stroma), respectively. Magnification, × 10.](bjc2014446f2){#fig2}

![**Analysis of CD68, CD163 and CD11b cell number in samples from *n*=12 primary tumours and their matched local recurrence.** (**A**) We did not observe a difference in CD68+ or CD163+ cell influx in the recurrent samples compared with primary tumours . In contrast, there was a significant increase (*P*=0.0097) in CD11b+ cell infiltration in recurrent tumours compared with their matched primary tumour samples. (**B**) Cell number in each of the 12 patients (No.1--12) is shown as indicated. Columns/points, median; bars, s.d. (**C**) Example of CD11b+ expression in primary tumour (left) and its matched recurrence sample (right). Magnification, × 10.](bjc2014446f3){#fig3}

###### Results of the immunohistochemical markers scoring

  **Marker**                                                 **CD68** ***N*** **(%)**   **CD163** ***N*** **(%)**   **CD11b** ***N*** **(%)**
  --------------------------------------------------------- -------------------------- --------------------------- ---------------------------
  Dichotomised labelling score[a](#t1-fn1){ref-type="fn"}          ⩽4 *vs* \>4                 ⩽4 *vs* \>4                 ⩽5 *vs* \>5
  Low score                                                         70 (66.0)                   59 (55.7)                   63 (59.4)
  High Score                                                        36 (34.0)                   47 (44.3)                   43 (40.6)

Dichotomised labelling (low *vs* high score) was based on the median value of marker\'s expression.

###### Patient and treatment characteristics

                           **Low CD68**   **High CD68**               **Low CD163**   **High CD163**           **Low CD11b**   **High CD11b**    
  ------------------------ -------------- --------------- ----------- --------------- ---------------- ------- --------------- ---------------- -------
  **Age**                                                                                                                                       
  \<60.6 years             37 (52.9%)     16 (44.4%)      0.269       30 (50.8%)      23 (48.9%)       0.500   28 (44.4%)      25 (58.1%)       0.118
  ⩾60.6 years              33 (47.1%)     20 (55.6%)                  29 (49.2%)      24 (51.1%)               35 (55.6%)      18 (41.9%)        
  **Gender**                                                                                                                                    
  Male                     55 (65.5%)     15 (68.2%)      0.512       47 (79.7%)      37 (78.7%)       0.547   51 (81%)        33 (76.7%)       0.387
  Female                   29 (34.5%)     7 (31.8%)                   12 (20.3%)      10 (21.2%)               12 (19%)        10 (23.3%)        
  **Fractionation mode**                                                                                                                        
  Normofractionated        55 (78.6%)     26 (72.2)       0.562       46 (78%)        35 (74.5%)       0.375   47 (74.6%)      34 (79.1%)       0.307
  HART                     13 (18.6%)     8 (22.2%)                   10 (16.9%)      11 (23.4%)               14 (22.2%)      7 (16.3%)         
  Completely hyperfr.      1 (1.4%)       0 (0%)                      0 (0%)          1 (2.1%)                 0 (0%)          1 (2.3%)          
  SIB                      0 (0%)         1 (2.8%)                    1 (1.7%)        0 (0%)                   0 (0%)          1 (2.3%)          
  Other                    1 (1.4%)       1 (2.8%)                    2 (3.4%)        0 (0%)                   2 (3.2%)        0 (0%)            
  **Tumour site**                                                                                                                               
  Oral cavity              17 (24.3%)     10 (27.8%)      0.384       13 (22%)        14 (29.8%)       0.384   17 (27%)        10 (23.3%)       0.782
  Oropharynx               33 (47.1%)     12 (33.3%)                  25 (42.4%)      20 (42.6%)               27 (42.9%)      18 (41.9%)        
  Hypopharynx              17 (24.3%)     10 (27.8%)                  18 (30.5%)      9 (19.1%)                15 (23.8%)      12 (27.9%)        
  Larynx                   3 (4.3%)       2 (5.6%)                    3 (5.1%)        3 (6.4%)                 3 (4.8%)        2 (4.7%)          
  Other                    0 (0%)         2 (5.6%)                    1 (1.7%)        1 (2.1%)                 1 (1.6%)        1 (2.3%)          
  **T-staging**                                                                                                                                 
  cT1-2                    7 (10%)        3 (8.3%)        0.541       4 (6.8%)        6 (12.8%)        0.237   6 (9.5%)        4 (9.3%)         0.623
  cT3-4                    63 (90%)       33 (91.7%)                  55 (93.2%)      41 (87.2%)               57 (90.5%)      39 (90.7%)        
  **N-staging**                                                                                                                                 
  cN0-1                    14 (20%)       1 (2.8%)        **0.003**   12 (20.3%)      3 (6.4%)         0.118   7 (11.1%)       8 (18.6%)        0.546
  cN2a-2b                  18 (25.7%)     20 (55.6%)                  19 (32.2%)      19 (40.4%)               23 (36.5%)      15 (34.9%)        
  cN2c-3                   38 (54.3%)     15 (41.7%)                  28 (47.5%)      25 (53.2%)               33 (52.4%)      20 (46.5%)        
  **Grading**                                                                                                                                   
  G1                       4 (5.7%)       1 (2.8%)        0.596       4 (6.8%)        1 (2.1%)         0.504   1 (1.6%)        4 (9.3%)         0.127
  G2                       55 (78.6%)     27 (75%)                    44 (74.6%)      38 (80.9%)               52 (82.5%)      30 (69.8%)        
  G3                       11 (15.7)      8 (22.2%)                   11 (18.6%)      8 (17%)                  10 (15.9%)      9 (20.9%)         
  **Smoking history**                                                                                                                           
  Yes                      37 (62.7%)     22 (46.8%)      0.164       33 (61.1%)      25 (49%)         0.133   29 (46%)        28 (54.9%)       0.176
  No                       22 (37.3%)     25 (53.2%)                  21 (38.9%)      26 (51%)                 34 (54%)        23 (45.1%)        

Abbreviations: HART=hyperfractionated accelerated radiotherapy; SIB=simultaneously-integrated boost.

Score was based on the median value marker expression; significant results have been marked with bold.

###### Univariate and multivariate analyses of prognostic factors in patients with HNSCC

                                            **Multivariate**                   
  ----------------------------- ----------- ------------------ ------- ------- -----------
  **OS**                                                                       
  CD68+ (low/high)              **0.017**   1.773              0.891   3.528   0.103
  CD163+ (low/high)             **0.007**   2.105              1.198   3.701   **0.010**
  CD11b+ (low/high)             0.565       1.129              0.624   2.042   0.688
  Grade (G1/2/G3)               0.924       0.610              0.306   1.214   0.159
  N-stage (N0-1/N2a-b/N2c-N3)   0.214       1.440              0.940   2.205   0.094
  T-stage (T1-2/T3-4)           0.228       0.476              0.202   1.123   0.090
  Tumour localisation           0.702       0.878              0.483   1.595   0.668
  Age (\<61/⩾61)                0.502       1.392              0.757   2.558   0.287
  Sex (male/female)             0.633       0.846              0.392   1.829   0.671
  **PFS**                                                                      
  CD68+ (low/high)              **0.010**   1.316              0.710   2.440   0.382
  CD163+ (low/high)             **0.006**   1.797              1.049   3.080   **0.033**
  CD11b+ (low/high)             0.252       1.224              0.693   2.160   0.487
  Grade (G1/2/G3)               0.637       0.740              0.361   1.515   0.410
  N-stage (N0-1/N2a-b/N2c-N3)   0.160       1.311              0.851   2.021   0.219
  T-stage (T1-2/T3-4)           0.282       0.610              0.259   1.434   0.257
  Tumour localisation           0.587       0.733              0.407   1.320   0.300
  Age (\<61/⩾61)                0.260       0.937              0.527   1.668   0.826
  Sex (male/female)             0.753       0.82               0.380   1.771   0.614
  **LFFS**                                                                     
  CD68+ (low/high)              **0.006**   1.466              0.798   2.693   0.217
  CD163+ (low/high)             **0.007**   1.778              1.038   3.047   **0.036**
  CD11b+ (low/high)             0.275       1.187              0.674   2.093   0.553
  Grade (G1/2/G3)               0.977       0.681              0.333   1.394   0.293
  N-stage (N0-1/N2a-b/N2c-N3)   0.247       1.339              0.869   2.064   0.185
  T-stage (T1-2/T3-4)           0.370       0.614              0.263   1.429   0.257
  Tumour localisation           0.581       0.685              0.378   1.243   0.213
  Age (\<61/⩾61)                0.864       1.021              0.577   1.808   0.942
  Sex (male/female)             0.460       0.771              0.362   1.643   0.501
  **DMFS**                                                                     
  CD68+ (low/high)              **0.011**   1.300              0.678   2.492   0.430
  CD163+ (low/high)             **0.010**   1.807              1.032   3.162   **0.038**
  CD11b+ (low/high)             0.343       1.194              0.656   2.173   0.562
  Grade (G1/2/G3)               0.984       0.694              0.329   1.465   0.338
  N-stage (N0-1/N2a-b/N2c-N3)   0.245       1.390              0.879   2.198   0.159
  T-stage (T1-2/T3-4)           0.224       0.535              0.226   1.266   0.155
  Tumour localisation           0.856       0.924              0.506   1.686   0.796
  Age (\<61/⩾61)                0.753       1.184              0.648   2.165   0.583
  Sex (male/female)             0.696       0.842              0.387   1.833   0.665

Abbreviations: CI=confidence interval; DMFS=distant metastases-free survival; HNSCC=head neck squamous cell carcinoma; HR=hazard ratio; LFFS=local failure-free survival; OS=overall survival; PFS=progression-free survival.

Significant results have been marked with bold.
